Brazil Semaglutide Race Opens as Anvisa Clears Five Pens

Brazil · Business Key Facts —Patent expiry Novo Nordisk’s semaglutide patent expired in March 2026, ending exclusivity for Ozempic and Wegovy in Brazil. —New registrations Anvisa registered five new semaglutide pens on July 29, 2026: Semavy, Owozy, Seemasun, Zempneo, and Orsema, joining EMS’s earlier Ozivy. —Regulatory classification Under Brazilian law these are new synthetic semaglutide…